RT Journal Article
SR Electronic
T1 Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: a randomised controlled trial
JF Thorax
JO Thorax
FD BMJ Publishing Group Ltd and British Thoracic Society
SP 496
OP 499
DO 10.1136/thoraxjnl-2018-212609
VO 74
IS 5
A1 Sylvain Recoquillon
A1 Jean-Louis Pépin
A1 Bruno Vielle
A1 Ramaroson Andriantsitohaina
A1 Vanessa Bironneau
A1 Frédérique Chouet-Girard
A1 Bernard Fleury
A1 François Goupil
A1 Sandrine Launois
A1 M Carmen Martinez
A1 Nicole Meslier
A1 Xuan-Lan Nguyen
A1 Audrey Paris
A1 Pascaline Priou
A1 Renaud Tamisier
A1 Wojciech Trzepizur
A1 Frédéric Gagnadoux
YR 2019
UL http://thorax.bmj.com/content/74/5/496.abstract
AB Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea–Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night).Trial registration number NCT01426607.